UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 19 von 89
Datensatz exportieren als...
BibTeX
Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia
Cancer, 2006-04, Vol.106 (7), p.1569-1580
Thomas, Deborah A.
Faderl, Stefan
O'Brien, Susan
Bueso‐Ramos, Carlos
Cortes, Jorge
Garcia‐Manero, Guillermo
Giles, Francis J.
Verstovsek, Srdan
Wierda, William G.
Pierce, Sherry A.
Shan, Jianqin
Brandt, Mark
Hagemeister, Fredrick B.
Keating, Michael J.
Cabanillas, Fernando
Kantarjian, Hagop
2006
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Thomas, Deborah A.
Faderl, Stefan
O'Brien, Susan
Bueso‐Ramos, Carlos
Cortes, Jorge
Garcia‐Manero, Guillermo
Giles, Francis J.
Verstovsek, Srdan
Wierda, William G.
Pierce, Sherry A.
Shan, Jianqin
Brandt, Mark
Hagemeister, Fredrick B.
Keating, Michael J.
Cabanillas, Fernando
Kantarjian, Hagop
Titel
Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia
Ist Teil von
Cancer, 2006-04, Vol.106 (7), p.1569-1580
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2006
Quelle
Wiley-Blackwell Journals
Beschreibungen/Notizen
BACKGROUND Adult Burkitt‐type lymphoma (BL) and acute lymphoblastic leukemia (B‐ALL) are rare entities composing 1% to 5% of non‐Hodgkin lymphomas NHL) or ALL. Prognosis of BL and B‐ALL has been poor with conventional NHL or ALL regimens, but has improved with dose‐intensive regimens. METHODS To evaluate the addition of rituximab, a CD20 monoclonal antibody, to intensive chemotherapy in adults with BL or B‐ALL, 31 patients with newly diagnosed BL or B‐ALL received the hyper‐fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper‐CVAD) regimen with rituximab. Their median age was 46 years; 29% were 60 years or older. Rituximab 375 mg/m2 was given on Days 1 and 11 of hyper‐CVAD courses and on Days 1 and 8 of methotrexate and cytarabine courses. RESULTS Complete remission (complete response [CR]) was achieved in 24 of 28 (86%) evaluable patients; 3 had a partial response, and 1 had resistant disease. There were no induction deaths. The 3‐year overall survival (OS), event‐free survival, and disease‐free survival rates were 89%, 80%, and 88%, respectively. Nine elderly patients achieved CR with all of them in continuous CR (except 1 death in CR from infection), with a 3‐year OS rate of 89%. Multivariate analysis of current and historical (those treated with hyper‐CVAD alone) groups identified age and treatment with rituximab as favorable factors. CONCLUSIONS The addition of rituximab to hyper‐CVAD may improve outcome in adult BL or B‐ALL, particularly in elderly patients. Cancer 2006. © 2006 American Cancer Society. The addition of rituximab to hyper‐CVAD may improve outcome in adult Burkitt lymphoma and acute lymphoblastic leukemia, particularly in elderly patients.
Sprache
Englisch
Identifikatoren
ISSN: 0008-543X
eISSN: 1097-0142
DOI: 10.1002/cncr.21776
Titel-ID: cdi_crossref_primary_10_1002_cncr_21776
Format
–
Schlagworte
acute lymphoblastic leukemia
,
adult Burkitt lymphoma
,
Antibodies, Monoclonal - therapeutic use
,
Antibodies, Monoclonal, Murine-Derived
,
Antineoplastic agents
,
Antineoplastic Agents - therapeutic use
,
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
,
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
,
Biological and medical sciences
,
Burkitt Lymphoma - drug therapy
,
B‐ALL
,
chemoimmunotherapy
,
Combined Modality Therapy
,
Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
,
Cyclophosphamide - administration & dosage
,
Dexamethasone - administration & dosage
,
Doxorubicin - administration & dosage
,
Drug Administration Schedule
,
Female
,
Humans
,
hyper‐CVAD
,
Immunotherapy
,
Infusions, Intravenous
,
Male
,
Medical sciences
,
Middle Aged
,
Pharmacology. Drug treatments
,
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
,
Rituximab
,
Survival Analysis
,
Treatment Outcome
,
Tumors
,
Vincristine - administration & dosage
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX